StreetAlpha.app
Home › Stocks › KNSA

Kiniksa Pharmaceuticals International, plc (KNSA)

Healthcare
$95.11
▲ +0.93%
LAST CLOSE · NOV 17

Kiniksa Pharmaceuticals develops and sells ARCALYST, a treatment for recurrent pericarditis and other inflammatory conditions. It last closed at $95.11 on Nov 17, up 0.93% on the day. The average 12-month price target from 5 analysts is $110.00 (+15.7% from the last close), with a high of $122.00 and a low of $101.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $1000K, the largest $1000K.

AI Auto Pilots
Is KNSA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$946.0M
+58.2% vs a year ago
Net income
$109.6M
+205.1% vs a year ago
EPS (diluted)
$1.32
+193.3% vs a year ago
Free cash flow
$197.2M
20.8% margin
Balance sheet
Cash & equivalents
$81.7M
At Sep 30
Shareholder equity
$710.2M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $38.5M$38.5MFY2021FY2022: $220.2M$220.2MFY2022FY2023: $270.3M$270.3MFY2023FY2024: $423.2M$423.2MFY2024FY2025: $677.6M$677.6MFY2025

From KNSA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 27). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on KNSA in the past 90 days
Average 12-month target
$110.00
▲ 15.7% upside

Based on 5 analysts who set a price target on KNSA in the past 90 days. The average target is $110.00, with a high of $122.00 and a low of $101.00, compared with the last close of $95.11.

Low $101.00Avg $110.00High $122.00
Blue marker: last close $95.11
Highest target$122.00
Average target$110.00
Lowest target$101.00
Latest rating changes
TD CowenMaintained
Nov 17Buy$115
JP MorganTarget raised
Oct 30Buy$107 → $122
Goldman SachsTarget raised
Oct 28Buy$90 → $101
WedbushTarget raised
Oct 28Buy$99 → $102
Wells FargoMaintained
Oct 28Buy$110
DateFirmActionRatingPrice target
Nov 17TD CowenMaintainedBuy$115
Oct 30JP MorganTarget raisedBuy$107 → $122
Oct 28Goldman SachsTarget raisedBuy$90 → $101
Oct 28WedbushTarget raisedBuy$99 → $102
Oct 28Wells FargoMaintainedBuy$110
Loading…

Technical Analysis

KNSA · as of the Nov 17 close · updated after every close
Uptrend

The stock is 4% above its 20 day and 13% above its 50 day average. It is 33% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 58). The nearest support is the Pivot at $94.57, and the nearest resistance the Pivot R1 at $95.79.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 4.5%/day
Key levels
$99.3152 week high+4.4%
$98.48Swing high (Oct 30)+3.5%
$95.79Pivot R1+0.7%
$95.11Last close
$94.57Pivot−0.6%
$93.90Pivot S1−1.3%
$90.9120 day average−4.4%
$87.30Swing low (Nov 5)−8.2%
$82.8650 day average−12.9%
$77.55100 day average−18.5%
$63.33200 day average−33.4%
$37.0252 week low−61.1%
Indicators
RSI (14)57.96Middle of its rangeNeutral
MACD4.03Below its signal lineBearish
Stochastic68.4Middle of its rangeNeutral
ADX (14)19.1No clear trend
Williams %R-35.0Oversold below −80, overbought above −20Neutral
CCI (20)46.4Oversold below −100, overbought above 100Neutral
Rate of change+1.9%Change over 10 sessionsBullish
ATR (14)$4.30Typical daily range, 4.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for KNSA

What happened before

See how KNSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow KNSA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How KNSA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in KNSA in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$1000K
Largest print
$1000K
Loading…

KNSA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲182 buying vs 109 selling
  • ●Shares held by funds +0.9%
  • ▲Funds holding +38
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding304266+14.3%
In funds' top 1065+20.0%
Held by funds–––
New / increased64 / 11868 / 86+18.2%
Reduced / sold out84 / 2581 / 26+1.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KNSA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KNSA is in one of them and how their past KNSA trades turned out.

KNSA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KNSA in an article yet. Here's the latest on the wider market.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals is a drug developer based in London that focuses on cardiovascular diseases. Its main product, ARCALYST, is approved in the United States for recurrent pericarditis, an inflammatory condition of the heart lining, and for certain autoinflammatory syndromes. The company sells ARCALYST in the United States through specialty pharmacies, has licensed partners in other regions, and is developing KPL-387, an investigational antibody that targets the same inflammation pathway. Its customers are patients and the doctors who treat them.

Headquarters
London